# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Financial GuidanceCommercial revenue for the second quarter 2024 is expected to be in the range of $14.3 to $15.3 millionCommer...
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.4...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The D...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday.
U.S. stock futures were lower this morning, with the Dow futures falling over 150 points on Thursday.
BTIG analyst Ryan Zimmerman downgrades AVITA Medical (NASDAQ:RCEL) from Buy to Neutral.